EDMONTON, ALBERTA, Apr 22, 2008 (MARKET WIRE via COMTEX) -- Ceapro Inc. (CA:CZO: news, chart, profile) announced today the completion of a new marketing partnership and distribution agreement with Korean firm, East Hill Corporation. The agreement encompasses Ceapro's current range of seven, certified organic, natural active ingredients.
Founded in 1996, East Hill develops and distributes ingredients for the health and beauty industries, from facilities in CheongBuk Province, South Korea. East Hill's many customers include the top three Korean cosmetic companies: Amore Pacific, LG (H&H) and the Face Shop.
Said Mr IK Joe, President of East Hill, "We are very pleased to enter into this agreement with Ceapro, and look forward to introducing their natural and organic products to our large market for cosmetics: the South Korean per capita consumption of beauty products ranks in the top five in the world. We expect the combination of Ceapro's quality products and East Hill's strengths in marketing and formulation in the Asian market will provide the foundation for a very successful long-term partnership."
Ceapro President and CEO, Dr. Mark Redmond reaffirmed the Company's growth strategy of international market expansion. "We have announced recently distribution partnerships in France and the United States. Working with East Hill continues our strategy of partnering with notable regional and market sector specialists. By positioning our new compounds in the $8 billion global market for natural organic cosmetics we fully expect to win over new customers to our products and expertise."
About Ceapro Inc.
Ceapro Inc. is a Canadian growth-stage biotechnology company whose primary business activities relate to the development and commercialization of organic products for medical, cosmetic and animal health industries using proprietary technology and natural, renewable resources. We will also be applying our technology to become an active participant in the bio-energy sector. We have introduced health and wellness services employing our CeaProve(R) diagnostic technology. To learn more about Ceapro, visit www.ceapro.com
The TSX has neither approved nor disapproved of the information contained herein. This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.